Linaclotide
Also known as: Linzess, Constella
Key Facts: Linaclotide
- Category
- Hormonal
- FDA Status
- FDA Approved
- Clinical Status
- FDA Approved - IBS-C and chronic idiopathic constipation (adults); pediatric IBS-C ages 7+ (Nov 2025) and pediatric functional constipation ages 2+ (May 2026)
- Administration
- Oral capsule on empty stomach
- Typical Dose
- Limited community data available
- Frequency
- See research protocols
- Duration
- Long-term / chronic use
Mechanism of Action
Linaclotide latches onto guanylate cyclase-C receptors lining the inside of the intestine. That switch raises a signaling molecule called cyclic GMP inside the gut-lining cells, which pushes chloride and bicarbonate out into the intestinal channel and slows sodium reabsorption. Water follows the salt into the gut, so stool gets softer and transit speeds up. The same cyclic GMP also leaks out to the nerve endings that sense pain in the gut wall and quiets them down, which is the proposed explanation for the pain relief seen in IBS-C, supported by animal nociceptor studies. The peptide is barely absorbed into the bloodstream, so its action stays mostly local to the gut.
Research Summary
The human evidence here is solid and regulatory-grade. Two large phase 3 randomized, double-blind, placebo-controlled trials in IBS-C (around 800 patients each, 12 and 26 weeks) showed that 290 micrograms once daily beat placebo on the strict FDA co-primary endpoints combining abdominal pain reduction and more complete spontaneous bowel movements, with abdominal pain or discomfort responder rates around 54 percent versus roughly 40 percent on placebo. Separate phase 3 work supported lower doses such as 72 micrograms for chronic idiopathic constipation over 12 weeks. Across the program, serious adverse events were rare and not clearly above placebo. The most common and predictable side effect is diarrhea, which is just the drug working too well and is the main reason people stop it. Overall this is a well-studied, approved therapy, not a speculative peptide.
Dosing Information
Typical Dosingⓘ
Community experience
Limited community data available
See research dosing
See research protocols
Research Dosingⓘ
Scientific studies
FDA-approved dosing
Doses from Studies
290 mcg daily (IBS-C)
145 mcg daily (CIC)
72 mcg available
Duration
Long-term / chronic use
Administration
Oral capsule on empty stomach
Timing & Administration
Best Time to Take
Morning or as directed
Follow recommended protocol
Food Recommendation
With or without food
Why This Timing?
Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.
Possible Side Effects
Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.
- ●Diarrhea (up to 50%)
- ●Abdominal pain
- ●Flatulence
- ●Fecal incontinence
- ●CONTRAINDICATED in children <2 years
- ●FDA approved (Linzess)
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3504311/
- https://pubmed.ncbi.nlm.nih.gov/23116208/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC5770595/
- https://pubmed.ncbi.nlm.nih.gov/21651347/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC3957218/
Research This Peptide Further
Frequently Asked Questions
What does Linaclotide do?
Linaclotide (brand name Linzess in the US, Constella in Europe) is a 14-amino-acid synthetic peptide and a guanylate cyclase-C agonist, FDA-approved in August 2012. It is a real prescription gut drug, taken once daily by mouth, for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. It does two things at once: it gets sluggish bowels moving and it dials down the abdominal pain that comes with IBS.
How does Linaclotide work?
Linaclotide latches onto guanylate cyclase-C receptors lining the inside of the intestine. That switch raises a signaling molecule called cyclic GMP inside the gut-lining cells, which pushes chloride and bicarbonate out into the intestinal channel and slows sodium reabsorption. Water follows the salt into the gut, so stool gets softer and transit speeds up. The same cyclic GMP also leaks out to the nerve endings that sense pain in the gut wall and quiets them down, which is the proposed explanation for the pain relief seen in IBS-C, supported by animal nociceptor studies. The peptide is barely absorbed into the bloodstream, so its action stays mostly local to the gut.
Is Linaclotide FDA approved?
Yes, Linaclotide is FDA approved. FDA Approved - IBS-C and chronic idiopathic constipation (adults); pediatric IBS-C ages 7+ (Nov 2025) and pediatric functional constipation ages 2+ (May 2026)
What are the side effects of Linaclotide?
Reported side effects include: Diarrhea (up to 50%), Abdominal pain, Flatulence, Fecal incontinence, CONTRAINDICATED in children <2 years. Individual responses vary based on dosage, duration, and personal health factors.
What is the typical dose of Linaclotide?
Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Oral capsule on empty stomach. Community-reported doses. Not medical advice. Consult healthcare provider.
Related Peptides
Peptides commonly compared with Linaclotide or used in similar applications.
Oxytocin
FDAOxytocin is a 9-amino-acid hormone made in the hypothalamus, famous as the chemistry behind labor contractions, breastfeeding, and social bonding. As an injectable drug it is FDA-approved to induce labor and control postpartum bleeding, but the intranasal 'love hormone' versions sold for trust, anxiety, and autism are experimental and the human results are genuinely mixed. The hype runs well ahead of the evidence.
HormonalGonadorelin
FDAGonadorelin is a synthetic copy of natural GnRH (gonadotropin-releasing hormone), a 10-amino-acid peptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) that tells the pituitary to release LH and FSH. It is FDA-approved for evaluating pituitary function and has historical use in inducing ovulation. In the peptide world it is mostly used off-label to keep the testes working during testosterone replacement, and the catch is that timing matters enormously: pulse it and you stimulate, give it continuously and you shut the system down.
HormonalLeuprolide
FDALeuprolide (brand name Lupron) is a synthetic GnRH agonist, a modified peptide about 20 times more potent than natural GnRH, and it is FDA-approved for advanced prostate cancer, endometriosis, uterine fibroids, and central precocious puberty. The clever part is counterintuitive: it works by overstimulating the GnRH system so hard that the pituitary shuts down sex hormone production. It is a real, long-established prescription drug, not a research peptide, and it carries meaningful side effects from the low-hormone state it creates.
HormonalDesmopressin
FDADesmopressin (dDAVP) is a synthetic tweak of the natural hormone vasopressin, redesigned to keep the water-retaining effect while dropping most of the blood-pressure effect. It is a long-established FDA-approved drug used for central diabetes insipidus, bedwetting and nocturia, and certain bleeding disorders like von Willebrand disease and mild hemophilia A. This is settled medicine, not an experimental peptide, and its main real-world danger is straightforward: it can drop your blood sodium dangerously low if you drink too much fluid on it.
HormonalOctreotide
FDAOctreotide is a synthetic eight-amino-acid mimic of the natural hormone somatostatin, the body's main 'off switch' for hormone secretion. It shuts down excess growth hormone, so it is a frontline FDA-approved drug for acromegaly, and it also tames the flushing and diarrhea of hormone-secreting carcinoid and other neuroendocrine tumors. This is real, approved medicine with decades of clinical data behind it, sold as Sandostatin (injectable, since 1988), Sandostatin LAR (monthly depot), and Mycapssa (oral capsule, approved 2020).
HormonalLanreotide
FDALanreotide is an eight-amino-acid somatostatin analog, a close cousin of octreotide, given as a long-acting deep-injection gel (Somatuline Depot/Autogel) usually once a month. It is FDA-approved for acromegaly and for gastroenteropancreatic neuroendocrine tumors, and it carries an approval for carcinoid syndrome. It is established prescription medicine, not an experimental compound.
HormonalWant updates on Linaclotide research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.